When resident teams included experienced fourth-year trainees, the resident/attending pairs cut overall median report turnaround times by seven minutes versus attending-only efforts.

The FDA has cleared Polarean Imaging’s xenon gas-based MRI contrast agent for evaluating pulmonary function in patients aged 12 years and up.

Healthcare stakeholders throughout U.S. medicine, including radiology leaders, aren’t waiting for the ink to dry before speaking their minds.

A molecular contrast agent previously cleared for use during surgery for ovarian cancer may now be used in similar fashion during lung operations.

A population-level study featuring multi-organ MRI has confirmed that problems in any of three major organs—the heart, brain or liver—tend to co-occur with unfavorable findings in either or both of the other two.

A commercially available AI package has proven adept at distinguishing between two closely similar but unequally urgent conditions on chest X-rays.

The FDA has cleared software that automatically assesses density of breast tissue on mammography.

MRI scanner OEMs will soon face increased pressure to differentiate machines in their R&D pipelines with superconducting magnets, open designs, AI integrations and—maybe most challenging—potential for portability.